future earnings now take over mcap, page-48

Hi Champ

Orders for anti-virals were very strong before any pandemic was declared. Infact the market PRIOR to the current pandemic was over USD6bn. The trouble for Biota was relenza was playing second to tamiflu which gained over 85% market share.

Now governments are seeing side effects in tamiflu and widespread H1N1 resistance they are looking to Relenza. Media reports suggest 50:50 is possible. the current pandemic in my opinion will only expand the anti-viral market i.e. bigger overall size and demand for more compounds (including ones like Peramivir).

It's an exciting time for Biota, let's see how well GSK promote Relenza production on Wednesday night.

Good luck all.